SCHEMBL25920567

SCHEMBL25920567

COC(=O)c1cc(C)nc(NC2CCC(C)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.45
KCNH2 Q12809 1/20 0.45
AURKB Q96GD4 1/20 0.45
MCHR1 Q99705 11/20 0.42
ADRA2A P08913 3/20 0.41
HRH1 P35367 3/20 0.41
ADRA1A P35348 2/20 0.41
HTR2B P41595 2/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
RBP4 P02753 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25920566 0.86 MCHR1 (0.42) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL25925683 0.83 CNR1 (0.45) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL1178837 0.80 MCHR1 (0.45) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL18036085 0.79 ALDH1A1 (0.46) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL7364277 0.77 MCHR1 (0.40) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL7357755 0.77 MCHR1 (0.43) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL2713731 0.75 HSD17B10 (0.49) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL2369879 0.74 DNM2 (0.49) CNR1KCNH2AURKBMCHR1ADRA2A
SCHEMBL21200772 0.72 RBP4 (0.46) KDM4EALDH1A1MAPTPKMMEN1
SCHEMBL2715951 0.72 CYP1A2 (0.55) SMN1; SMN2KDM4EALDH1A1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 CNR1 4223/4885KCNH2 4579/4885AURKB 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.